Topics

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

10:53 EST 14 Feb 2020 | OncLive

Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Original Article: Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

NEXT ARTICLE

More From BioPortfolio on "Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy"

Quick Search

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...